Neramexane

Summary

Neramexane (CHEMBL2110954) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 169.31 Da · C11H23N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110954
Name	Neramexane
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6433106
Molecular formula	C11H23N
Molecular weight	169.31
InChIKey	OGZQTTHDGQBLBT-UHFFFAOYSA-N

SMILES: CC1(CC(CC(C1)(C)N)(C)C)C

IUPAC name: 1,3,3,5,5-pentamethylcyclohexan-1-amine

Also known as: Neramexane, Neramexano, NERAMEXANE

Parent form; salt/anhydrous children: CHEMBL2106798

Patent coverage: 336 distinct patent families (940 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00090116	PHASE3	COMPLETED	The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer’s Disease
NCT00405886	PHASE2	COMPLETED	Neramexane for Tinnitus
NCT00915174	PHASE1	COMPLETED	Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects
NCT00936026	PHASE1	COMPLETED	Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane
NCT00955760	PHASE1	COMPLETED	Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate
NCT00972127	PHASE1	COMPLETED	Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen
NCT00978614	PHASE1	COMPLETED	Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects
NCT00983099	PHASE1	COMPLETED	Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects
NCT01109680	PHASE1	COMPLETED	A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).